ARTICLE | Clinical News

Eli Lilly preclinical data

April 3, 1995 7:00 AM UTC

The Indianapolis company said that a new antibiotic it is developing has the potential to overcome resistant gram-positive bacteria, including those that are no longer sensitive to vancomycin.

The compound has shown activity in test tubes and in animal studies against enterococci resistant to vancomycin and telcoplanin. The new drug also kills Staphylococcus aureus and other gram-positive bacteria resistant to penicillin and methicillin. ...